

CORRECTION

[View Article Online](#)
[View Journal](#) | [View Issue](#)



Cite this: *Nanoscale*, 2025, **17**, 2912

DOI: 10.1039/d4nr90241f
rsc.li/nanoscale

Correction: Camptothecin-based prodrug nanomedicines for cancer therapy

Renshuai Zhang,^a Jing Yu,^b Zhu Guo,^{*a,c} Hongfei Jiang^{*a} and Chao Wang^{*a}

Correction for 'Camptothecin-based prodrug nanomedicines for cancer therapy' by Renshuai Zhang *et al.*, *Nanoscale*, 2023, **15**, 17658–17697, <https://doi.org/10.1039/D3NR04147F>.

The authors regret that project funders were omitted from the Acknowledgements section in the published article. The corrected Acknowledgements section should read as follows.

This study was supported by the National Natural Science Foundation of China (82202848), the Shandong Postdoctoral Science Foundation (SDCX-ZG-202203015), and the Natural Science Foundation of Shandong Province (grant no. ZR2021MC189).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aCancer Institute of The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266061, China. E-mail: guozhugz@126.com, jianghongfei@qdu.edu.cn, wangchao@qdu.edu.cn

^bQingdao Hospital, University of Health and Rehabilitation Sciences, Qingdao Municipal Hospital, Qingdao, 266071, China

^cThe Affiliated Hospital of Qingdao University, Qingdao 266061, China

